Table 1 Baseline characteristics of the patients
Characteristic | n = 100 |
|---|---|
Male, n (%) | 77 (77) |
Age (years), median (IQR) | 47 (40–58) |
Origin, n (%) | |
Caucasian | 61 (61%) |
Sub-saharian africa | 32 (32%) |
Others | 7 (7%) |
Time since HIV diagnosis (years), median (IQR) | 10.3 (5–17) |
CDC classification, n (%) | |
A | 62 (62%) |
B | 14 (14%) |
C | 24 (24%) |
CD4 nadir cell count (cells/mm3), median (IQR), n = 99 | 233 (122–372) |
CD4 cell count at screening (cells/mm3), median (IQR) | 642 (473–875) |
Antiretroviral therapy duration (years), median (IQR) | 8.5 (4.7–14.5) |
Duration of last ARV therapy (years), median (IQR) | 3.3 (1.6–5.6) |
ARV therapy at screening, n (%) | |
2 NRTIs + Protease inhibitor | 40 (40%) |
2 NRTIs + 1 NNRTI | 13 (13%) |
2 NRTIs + 1 INSTI | 47 (47%) |
2NRTIs + RAL BID | 32 (32%) |
Active hepatitis co-infection, n (%) | |
Hepatitis B virus (Positive HBs Ag) | 5 (5%) |
Hepatitis C virus (Positive RNA) | 0 (0%) |
BMI (kg/m2), mean (± sd) | 26.6 (5.6) |
Creatinine (µmol/l), mean (± sd), n = 99 | 82 (± 17.12) |
eGFR (MDRD) (mL/min), mean (± sd), n = 99 | 95.70 (± 23.67) |
Total cholesterol (mmol/L), mean (± sd), n = 98 | 4.76 (± 0.95) |
LDL cholesterol (mmol/L), mean (± sd), n = 95 | 2.86 (± 0.73) |
HDL cholesterol (mmol/L), mean (± sd), n = 96 | 1.32 (± 0.54) |
Triglycerides (g/l) mean (± sd), n = 98 | 1.43 (± 0.88) |
Glycaemia (mmol/L), mean (± sd), n = 85 | 5.33 (± 1.28) |